Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy

TRANSFUSION(2023)

引用 0|浏览1
暂无评分
摘要
Nirupama Singh received a consultant fee from Gilead Sciences. Julie Staves received support for attending meetings from Immulab and is Chair of the Transfusion Laboratory Manager Subgroup of the UK National Blood Transfusion Committee. Jill R. Storry received support from the Swedish Research Council, received honorarium from Ortho Clinical Diagnostics, Grifols Diagnostic Solutions, and Wiley, is Vice President of the International Society of Blood Transfusion, is a chapter lead (Immunohematology; 21st Edition Blood Guide) for the Council of Europe European Directorate for the Quality of Medicines and HealthCare, and is an owner of BLUsang AB/receives royalties from a patent. Jason Dinoso is an employee of Gilead Sciences. Camille Renard is an employee of and owns stock in Gilead Sciences. Parul Doshi is an employee of Gilead Sciences. Lisa Johnson is an employee of and owns stock in Gilead Sciences. Connie Westhoff received a consultant fee from Gilead Sciences and is a participant on the Data and Safety Monitoring Board for the Cerus Pathogen Inactivation System. Michael F. Murphy received a consultant fee from Gilead Sciences and is a participant on the Haemonetics Scientific Advisory Council.
更多
查看译文
关键词
ABO typing interference, anti-CD47, Hu5F9-G4, magrolimab, pretransfusion testing interference, serological interference, transfusion interference
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要